Literature DB >> 2192873

Acquired hyperlipidemia (secondary dyslipoproteinemias).

A Chait1, J D Brunzell.   

Abstract

Acquired hyperlipidemia (secondary dyslipoproteinemias) results from underlying disorders that lead to alterations in plasma lipid and lipoprotein metabolism. Secondary dyslipoproteinemias may mimic primary forms of hyperlipidemia and can have similar consequences. They may result in increased predisposition to premature atherosclerosis or, when associated with marked hypertriglyceridemia, may lead to the development of pancreatitis and other features of the chylomicronemia syndrome. Diabetes mellitus and use of drugs such as diuretics, beta blockers, and estrogens are commonly encountered causes of secondary dyslipoproteinemia. Other conditions leading to acquired hyperlipidemia include hypothyroidism, renal failure, nephrotic syndrome, alcohol usage, and some rare endocrine and metabolic disorders. When secondary and familial forms of hypertriglyceridemia coexist, triglyceride removal mechanisms may be saturated and marked hypertriglyceridemia with fasting chylomicronemia might ensue. Treatment of the underlying condition, when possible, or discontinuation of the offending drugs usually leads to an improvement in the hyperlipidemia. Specific lipid-lowering therapy may be required in certain circumstances.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192873

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  16 in total

1.  Role of LXRs in control of lipogenesis.

Authors:  J R Schultz; H Tu; A Luk; J J Repa; J C Medina; L Li; S Schwendner; S Wang; M Thoolen; D J Mangelsdorf; K D Lustig; B Shan
Journal:  Genes Dev       Date:  2000-11-15       Impact factor: 11.361

2.  Statin resistant dyslipidemia in a patient treated with amiodarone.

Authors:  Ahmad Al-Sarraf; Min Li; Jiri Frohlich
Journal:  BMJ Case Rep       Date:  2011-10-11

3.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

4.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

Authors:  Christophe Marçais; Bruno Verges; Sybil Charrière; Valérie Pruneta; Micheline Merlin; Stéphane Billon; Laurence Perrot; Jocelyne Drai; Agnès Sassolas; Len A Pennacchio; Jamila Fruchart-Najib; Jean-Charles Fruchart; Vincent Durlach; Philippe Moulin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

6.  Fibrates for primary prevention of cardiovascular disease events.

Authors:  Alain J Nordmann; Ignacio Ferreira-González; Benjamin Kasenda; Ramon Saccilotto; Dirk Bassler; Neera Bhatnagar; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2012

7.  A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.

Authors:  Jeong Rang Park; Tae Sik Jung; Jung Hwa Jung; Gyeong-Won Lee; Me Ae Kim; Ki-Jong Park; Deok Ryong Kim; Se-Ho Chang; Soon Il Chung; Jong Ryeal Hahm
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

Review 8.  The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review.

Authors:  Emma O'Donnell; Mary Jane De Souza
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 9.  Fibrates for primary prevention of cardiovascular disease events.

Authors:  Tobias Jakob; Alain J Nordmann; Stefan Schandelmaier; Ignacio Ferreira-González; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-11-16

10.  Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats.

Authors:  Anurak Bunnoy; Kanokporn Saenphet; Saisamorn Lumyong; Supap Saenphet; Siriwadee Chomdej
Journal:  BMC Complement Altern Med       Date:  2015-03-28       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.